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The solute carrier 6 (SLC6) family of the human genome comprises transporters for neurotransmitters, amino acids, osmolytes
and energy metabolites. Members of this family play critical roles in neurotransmission, cellular and whole body homeostasis.
Malfunction or altered expression of these transporters is associated with a variety of diseases. Pharmacological inhibition of
the neurotransmitter transporters in this family is an important strategy in the management of neurological and psychiatric
disorders. This review provides an overview of the biochemical and pharmacological properties of the SLC6 family
transporters.
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Abbreviations
ADHD, attention deficit hyperactivity disorder; MDMA, 3,4-methylenedioxymetamphetamine; NMDA, N-methyl-D-
aspartate; NSS, neurotransmitter sodium symporters; OCD, obsessive-compulsive disorder; PDZ, PSD-95/Discs-large/ZO-1;
SSRI, selective 5-HT reuptake inhibitors; SNRI, 5-HT/noradrenaline reuptake inhibitors; TCA, tricyclic antidepressants
Introduction and overview
The solute carrier family 6 (SLC6) has 20 members in the
human genome (Chen et al., 2004; Broer, 2006). It comprises
transporters for neurotransmitters, proteinogenic amino
acids, betaine, taurine and creatine. The neurotransmitter
transporters were the first identified members, and hence, it is
also known as the family of neurotransmitter sodium sym-
porters (NSS) or the Na+/Cl--dependent transporter family
(Nelson, 1998; Beuming et al., 2006). Sequence similarity
allows subdividing the SLC6 family into four branches,
namely the GABA transporter branch, the monoamine trans-
porter branch and the amino acid transporter branches (I)
and (II) (Figure 1).
The GABA transporter branch contains transporters for
GABA, betaine, taurine and creatine. GABA is the major
inhibitory neurotransmitter in the brain. Inhibition of GABA
transporters will result in reduced clearance after synaptic
release and therefore enhances the action of inhibitory syn-
apses. Consequently, GABA transporter drugs are used to treat
not only seizures but also pain and anxiety (Clausen et al.,
2006). Taurine and betaine are both osmolytes (Lang, 2007),
and creatine is a storage compound for high-energy phos-
phate bonds to replenish ATP, particularly in muscle and
brain (Wallimann et al., 2011).
The monoamine transporter branch contains the neuro-
transmitter transporters for dopamine, 5-HT and noradrena-
line. These neurotransmitters play a modulatory role in the
CNS, affecting the activity of many pathways. They are par-
ticularly involved in the modulation of mood, aggression,
anxiety, depression, addiction, appetite, attention etc. (Hahn
and Blakely, 2007; Ramamoorthy et al., 2011). In general,
inhibition of monoamine transporters will result in reduced
clearance of monoamine transmitters after synaptic release,
resulting in a more intense and prolonged signal. Certain
drugs, in addition, elicit non-synaptic release of monoamine
neurotransmitters through the transporter.
The amino acid transporter branch (I) (Figure 1) com-
prises transporters for glycine, proline and the general amino
acid transporter ATB°,+ which is broadly specific for neutral (0)
and cationic (+) amino acids. Glycine is not only the major
inhibitory neurotransmitter in the spinal cord but also modu-
lates glutamatergic neurotransmission in the cortex by
binding to the NMDA receptor. The glycine transporter GlyT1
is widely expressed in the brain, and it is thought to modulate
glycine concentrations in the cortex, whereas GlyT2 is
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mainly found in the spinal cord. Glycine transporters are
targeted for treatment of neuropathic pain and schizophrenia
(Aragon and Lopez-Corcuera, 2005; Javitt, 2009). The proline
transporter PROT1 is almost exclusively expressed in the
brain, where its physiological role remains unclear. The
general amino acid transporter ATB0,+ is found in lung and
other epithelia and is thought to be involved in the clearance
of amino acids from secreted fluids (Mager and Sloan, 2003).
The amino acid transporter branch (II) contains amino
acid transporters involved in epithelial and brain amino acid
transport (Broer, 2008). Most members of this branch accept
a variety of neutral amino acids and therefore are involved in
amino acid homeostasis. The epithelial transporters mediate
the absorption of amino acids in the intestine and the
re-absorption of amino acids from the primary urine in the
kidney. The physiological role of the neural members of this
branch is ill-understood. Most likely, they provide metabolic
precursors for tricarboxylic acid cycle intermediates to allow
production of neurotransmitters.
Nomenclature
In addition to the SLC nomenclature, members of the SLC6
family are referred to by transporter names indicating sub-
strate preference. Some transporters have been named inde-
pendently by different groups or were renamed after their
function was discovered. Table 1 provides a list, ordered by
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Figure 1
Sequence similarity of SLC6 transporters. Peptide sequences of all human SLC6 members were aligned using T-coffee (Notredame et al., 2000),
and similarities were visualized using Treeview (Page, 1996). The main substrate for each transporter is shown next to the name. Subfamilies are
indicated.
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SLC number, which gives the most commonly used name
and alternative names. Some transporters have splice variants
resulting in a different peptide sequence, and these are listed
as well. In this review, transporter nomenclature follows Alex-
ander et al., (2011).
Substrates and mechanism
The four branches of the SLC6 family have different substrate
preferences (Figure 1 and Table 2). The monoamine trans-
porter branch comprises transporters for the biogenic amines
5-HT (SERT), noradrenaline (NET) and dopamine (DAT).
However, the substrate specificity is overlapping. DAT, for
instance, can also transport noradrenaline and NET has a
high affinity for dopamine (Gether et al., 2006). Furthermore,
a recent study has provided evidence that SERT is capable of
transporting dopamine, however, with lower substrate affin-
ity, higher maximum velocity and the requirement for higher
Na+ and Cl- to sustain transport (Larsen et al., 2011). Simi-
larly, there is substantial substrate promiscuity in the GABA
transporter branch. For example, b-alanine is not only a sub-
strate for the taurine transporter but also for GABA transport-
ers GAT-2 and GAT-3 and the amino acid transporter ATB0,+.
Table 1
Overview and nomenclature of the SLC6 family
SLC
number
Common
name Alias
Protein
variation Comments Reference
SLC6A1 GAT1 GATA Guastella et al. (1990)
SLC6A2 NET NAT1, NET1 C-t var1 Pacholczyk et al. (1991)
C-t var2
SLC6A3 DAT Giros et al. (1991); Kilty et al. (1991)
SLC6A4 SERT 5-HTT Blakely et al. (1991); Hoffman et al. (1991)
SLC6A5 GlyT2 GlyT2a Smith et al. (1992a)
GlyT2b
SLC6A6 TauT Liu et al. (1992a); Smith et al. (1992b); Uchida et al.
(1992)
SLC6A6P Pseudogene
SLC6A7 PROT Fremeau et al. (1992)
SLC6A8 CT1 CRTR Mayser et al. (1992); Guimbal and Kilimann (1993)
SLC6A9 GlyT1 GlyT1a Guastella et al. (1992); Liu et al. (1992b)
GlyT1b
GlyT1c
GlyT1d
GlyT1e
SLC6A10 CT2 Pseudogene
SLC6A11 GAT3 GATB Borden et al. (1992); Clark et al. (1992)
GAT4 (mouse)
SLC6A12 BGT1 GAT2 (mouse) Lopez-Corcuera et al. (1992); Yamauchi et al. (1992)
SLC6A13 GAT2 GAT3 (mouse) Borden et al. (1992)
SLC6A14 ATB0,+ b-alanine carrier Sloan and Mager (1999)
SLC6A15 B0AT2 v7-3, NTT73, SBAT1 Uhl et al. (1992)
SLC6A16 NTT5 Farmer et al. (2000)
SLC6A17 NTT4 RXT1 Uhl et al. (1992); Liu et al. (1993b)
SLC6A18 B0AT3 XT2, XTRP2 6 splice variants
in mouse
Wasserman et al. (1994); Nash et al. (1998)
SLC6A19 B0AT1 XT2s1 Broer et al. (2004)
SLC6A20 SIT1 IMINO, XT3, XTRP3 SLC6A20a Smith et al. (1995); Nash et al. (1998)
SLC6A20b
In rodents
SLC6A21P Pseudogene
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Glycine is a substrate of the specific glycine transporters
GlyT1 and GlyT2 and of the general amino acid transporters
B0AT1, B0AT3 and ATB0,+. Betaine is transported by BGT-1 and
also by SIT1. The overlapping substrate specificities within
the SLC6 family can be rationalized: All substrates of the
GABA transporter branch have a carboxyl group and an
amino group in the b- or g- position (Figure 1). In the case of
creatine, the amino group is part of the guanidino group, and
in the case of betaine, the amino-group is methylated. The
exception is taurine, which has a sulphonate group in the
b-position. Monoamine transporters accept decarboxylated
derivatives of aromatic amino acids, while all other members
transport amino acids. In some cases, site-directed mutagen-
esis of the substrate binding site has been used to alter the
substrate specificity of SLC6 transporters (Dodd and Christie,
2007; Vandenberg et al., 2007).
About half of the transporters in the SLC6 family
co-transport their substrate(s) together with two Na+ ions and
one Cl- ion (Table 2). The number of co-transported Na+ ions
can, however, vary from 1 (NET, SERT, B0AT1, B0AT2, NTT4) to
3 (GlyT2, BGT1). Furthermore, chloride is not universally
used as a co-transported ion (B0AT1, B0AT2, NTT4). SERT is
unique in its use of K+ as the anti-ported ion, resulting in an
overall electroneutral transport mechanism (Rudnick, 1998).
Two examples illustrate the fine-tuning of transport mecha-
nisms to physiological demands: GlyT1 uses the co-transport
Table 2
Endogenous substrates and transport mechanism
Transporter Endogenous substrate KM-values Mechanism Reference
SLC6A1/GAT1 GABA 11 mM 1S:2Na(S):1Cl(S) Loo et al. (2000)
SLC6A2/NET noradrenaline 0.4 mM 1S:1Na(S):1Cl(S) Pacholczyk et al. (1991); Gu et al.
(1996)dopamine 0.7 mM
SLC6A3/DAT dopamine 2.5 mM 1S:2Na(S):1Cl(S) Gu et al. (1994); Sonders et al.
(1997)noradrenaline 20 mM
SLC6A4/SERT 5-HT 0.45 mM 1S:1Na(S):1Cl(S):1 K(A) Ramamoorthy et al. (1993); Rudnick
(1998)
SLC6A5/GlyT2 glycine 27 mM 1S:3Na(S):1Cl(S) Roux and Supplisson (2000); Rees
et al. (2006)
SLC6A6/TauT taurine 5 mM 1S:2Na(S):1Cl(S) Ramamoorthy et al. (1994)
b-alanine 56 mM
SLC6A7/PROT proline 6–10 mM (rat) Not tested Fremeau et al. (1992)
SLC6A8/CT1 creatine 77 mM Not tested Nash et al. (1994)
SLC6A9/GlyT1 glycine 72 mM 1S:2Na(S):1Cl(S) Kim et al. (1994); Roux and
Supplisson (2000)
SLC6A10 pseudogene
SLC6A11/GAT3 GABA 7 mM 1S:2Na(S):1Cl(S) Borden et al. (1994); Karakossian
et al. (2005)
SLC6A12/BGT1 GABA 36 mM 1S:3Na(S):1Cl(S) Borden et al. (1995); Rasola et al.
(1995); Matskevitch et al. (1999)betaine 934 mM
SLC6A13/GAT2 GABA 3.7 mM 1S:2Na(S):1Cl(S) Sacher et al. (2002); Christiansen
et al. (2007)
SLC6A14/ATB0,+ Neutral and cationic
amino acids
Non-polar 6–100 mM 1S:2Na(S):1Cl(S) Sloan and Mager (1999)
Polar 100–600 mM
Cationic 76–100 mM
SLC6A15/B0AT2 BCAA, Met, Pro 40–200 mM 1S:1Na(S) Takanaga et al. (2005a); Broer et al.
(2006)
SLC6A16/NTT5 Unknown
SLC6A17/NTT4 BCAA, Met, Pro, Ala, Gln 360–5000 mM (rat) 1S:1Na(S) Parra et al. (2008); Zaia and Reimer
(2009)
SLC6A18/B0AT3 Gly, Ala 900–2300 mM (mouse) 1S:2Na(S):1Cl(S) Singer et al. (2009); Vanslambrouck
et al. (2010)
SLC6A19/B0AT1 Neutral amino acids 1–12 mM (mouse) 1S:1Na(S) Broer et al. (2004)
SLC6A20/IMINO Pro, OH-Pro, betaine 130 mM–200 mM
(rat/mouse)
1S:2Na(S):1Cl(S) Kowalczuk et al. (2005); Takanaga
et al. (2005b)
BCAA, branched chain amino acid; Mechanism: (S) symport (A) antiport; KM values are given for human isoforms unless indicated otherwise.
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of two Na+ ions, while GlyT2 uses three Na+-ions (both
together with Cl-) to accumulate glycine (Supplisson and
Roux, 2002). As a result, the accumulative power of GlyT1 is
less than that of GlyT2. GlyT1 is expressed in astrocytes in the
cortex and is thought to allow a significant extracellular
glycine concentration, enough to co-activate neighbouring
NMDA receptors through the glycine site. Small concentra-
tion changes of the co-transported ions or of the membrane
potential could thus result in glycine release or removal,
thereby modulating glutamatergic neurotransmission. GlyT2,
by contrast, is expressed in glycinergic neurons, allowing
optimal removal of the neurotransmitter from the synaptic
cleft, leaving only traces of extracellular glycine. The second
example is the occurrence of channel-like properties in
monoamine transporters. Due to the high affinity of these
transporters for their substrates, turnover is generally slow.
Channel-like properties may allow an increased transport rate
when neurotransmitter concentrations are elevated (Galli
et al., 1996; DeFelice and Goswami, 2007). The removal of
neurotransmitter is ensured by metabolic inactivation or
sequestration into synaptic vesicles. Inadvertently, the
channel-like mechanism is triggered by amphetamine
binding in the case of the DAT (Sitte et al., 1998; Kahlig et al.,
2005), which then results in release of the neurotransmitter,
explaining the pharmacological effects of amphetamine (Rob-
ertson et al., 2009; Leviel, 2011). A similar mechanism under-
lies 5-HT release by 3,4-methylenedioxymethamphetamine
(MDMA or ‘Ecstasy’) (Rudnick and Wall, 1992). Ion channel-
like features triggered by substrates and drugs are particularly
obvious in SERT, as its transport mechanism is electroneutral
and any currents observed are caused by uncoupled move-
ments of ions (Mager et al., 1994).
Pharmacology of SLC6 transporters
The pharmacology of the SLC6 family has been developed to
different extents (Table 3) (Gether et al., 2006; Iversen, 2006;
Kristensen et al., 2011). Due to their role as drug targets, a wide
variety of inhibitors and synthetic substrates are available for
monoamine transporters, whereas GABA and glycine trans-
porter pharmacology is less well developed. All other trans-
porters in the family remain largely unexplored (Table 4).
The first generation of monoamine transporter drugs were
identified in the 1950s and included the tricyclic antidepres-
sants (TCAs), such as imipramine and desimipramine, that
exert their action on SERT and/or NET (Moltzen and Bang-
Andersen, 2006). Because of side effects caused by additional
affinity for several different receptors and for cardiac sodium
channels (Gillman, 2007), these antidepressants have been
largely superseded by compounds devoid of ectopic binding.
These include compounds targeting solely SERT (’selective
5-HT reuptake inhibitors’, SSRIs) such as escitalopram, fluox-
etine and paroxetine (Wong and Bymaster, 1995), com-
pounds targeting solely NET (’selective noradrenaline
reuptake inhibitors’, NRIs), such as reboxetine (Andersen
et al., 2009) and compounds targeting both NET and SERT
(’dual uptake inhibitors’ or ‘5-HT/ noradrenaline reuptake
inhibitors’, SNRIs) including venlafaxine, desvenlafaxine and
duloxetine (Wong and Bymaster, 2002). Notably, these newer
classes of uptake inhibitors have not only shown efficacy in
treatment of major depression but also demonstrated their
usefulness in anxiety, obsessive-compulsive disorder (OCD)
and eating disorders. Interestingly, sibutramine, which has
been used as an appetite suppressant, might act as ‘a triple
uptake inhibitor’ because it is rapidly metabolized to its des-
methyl and didesmethyl congeners that display high affinity
for all three monoamine transporters (Glick et al., 2000).
More recently, specific triple uptake inhibitors are being
developed (Bettati et al., 2010).
The monoamine transporters are also target for illicit and
widely abused drugs such as cocaine and amphetamines.
Cocaine is a rapidly acting non-selective high-affinity inhibi-
tor of all three monoamine transporters (Eshleman et al.,
1999). Nonetheless, studies on DAT knock-out mice and
knock-in mice expressing a cocaine-insensitive DAT strongly
suggest that the stimulatory properties of cocaine are the
result of its interaction with DAT (Giros et al., 1996; Chen
et al., 2006). Several analogues of cocaine have been devel-
oped over the years with both higher affinity and improved
selectivity for the different monoamine transporters
(Table 3). These compounds have served and still serve as
important tool compounds; however, some are also consid-
ered candidates for treating cocaine addiction (Newman and
Kulkarni, 2002; Dutta et al., 2003; Loland et al., 2008). For
example, the benztropine analogue JHW007 does not possess
the same strong stimulatory properties as cocaine and was
found to antagonize the effect of cocaine on behaviour in rats
(Desai et al., 2005). Possibly, this is the result of a much
slower onset and longer duration of action than that of
cocaine, an effect that may be caused by JHW 007’s ability to
stabilize a different more closed conformation of the trans-
porter, compared with cocaine (Loland et al., 2008). The com-
pound modafinil, which is used to treat narcolepsy, is also a
DAT inhibitor with weaker action than cocaine and little
potential for abuse (Zolkowska et al., 2009). Accordingly,
modafinil might also be a promising therapeutic agent for
cocaine addiction (Dackis et al., 2005; Hart et al., 2008;
Minzenberg and Carter, 2008).
Some drugs targeting the monoamine transporters are not
simple inhibitors but are transporter substrates (Sitte et al.,
1998; Gether et al., 2006). They include amphetamine, meta-
mphetamine and MDMA, compounds that are capable of
promoting reverse transport of the endogenous substrate and
thus monoamine release via the monoamine transporters to
the extracellular environment (Fuller et al., 1988; Sulzer et al.,
2005). Amphetamine and metamphetamine act primarily on
DAT and NET, whereas SERT and NET are targets for MDMA
(Green et al., 2003; Sulzer et al., 2005). Amphetamine-
induced reverse transport is a complex process that is not
only the simple result of facilitated exchange (Pifl et al., 1999;
Scholze et al., 2002; Leviel, 2011) but is also likely to involve
a channel-like mode of the transporter (Kahlig et al., 2005).
The underlying mechanism appears to require binding of
Ca2+/calmodulin-dependent protein kinase IIa (CaMKIIa) to
the distal C-terminus of DAT (Fog et al., 2006). This binding
facilitates phosphorylation of N-terminal serine residues that
in turn changes the transporter from an ‘unwilling’ to a
‘willing’ state for reverse transport (Khoshbouei et al., 2004;
Fog et al., 2006). Binding of syntaxin1a to DAT might also be
critical for the process (Binda et al., 2008). Methylphenidate
is a derivative of amphetamine that is widely used in the
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treatment of attention-deficit hyperactivity disorder (ADHD).
This compound differs from amphetamine in not having
dopamine-releasing properties (Sulzer et al., 2005). It acts,
compared with cocaine, as a relatively weak DAT and NET
inhibitor, and as a consequence, this compound can also
have a potential in treating cocaine abuse (Goldstein et al.,
2010). Buproprion is another amphetamine derivative acting
primarily as an inhibitor at NET and DAT (Dwoskin et al.,
2006). It is registered as an atypical antidepressant and as
smoking cessation agent. Moreover, buproprion has a modest
weight-reducing effect that appears to be enhanced when
administered in combination with an opioid receptor antago-
nist (Dwoskin et al., 2006).
The GAT-1-specific inhibitor tiagabine is used to treat
seizures and neuropathic pain and is the only GABA trans-
porter inhibitor currently registered as a therapeutic agent
(Clausen et al., 2006). Tiagabine is also one of the only GABA
inhibitors showing selectivity among the GABA transporters,
although several inhibitors have been developed. In general,
GABA transporter inhibitors display rather low affinity and
selectivity for the transporters; and, thus, there is a strong
need for improved inhibitors of this subgroup of SLC6 trans-
porters (Table 3). Such new compounds might not only serve
as investigatory tool but also as new therapeutic agents; for
example, there is evidence that BGT-1 is an alternative target
to GAT-1 for treatment of epilepsy (Madsen et al., 2009).
In recent years, an increasing number of inhibitors of the
two glycine transporters GlyT1 and GlyT2 have been identi-
fied (Table 3). Development of these inhibitors has been
motivated by data indicating that blocking synaptic glycine
uptake is beneficial in psychotic disease and neuropathic pain
(Lechner, 2006; Dohi et al., 2009). The inhibitor N-methyl
glycine (sarcosine) was the basis for several potent inhibitors,
for instance (R)-NPTS and ORG 24598 (Mallorga et al., 2003).
Non-sarcosine GlyT1 inhibitors include LY2365109 (Perry
et al., 2008), CP-802 079 (Martina et al., 2004), Lu AA20465
(Smith et al., 2004) and SSR130800 (Boulay et al., 2008).
Overall, fewer inhibitors are known for GlyT2. The competi-
tive and selective inhibitor ORG 25543 was discovered first
(Caulfield et al., 2001) and followed by other classes of com-
pounds (Isaac et al., 2001).
The efficacy of inhibitors is also affected by functional
redundancy among neurotransmitter transporters. As a
result, use of a specific inhibitor of one transporter may have
a result different from that using a broadly specific inhibitor.
GAT1 is the most abundant GABA transporter in the cortex.
GAT-1-deficient mice show typical signs of increased inhibi-
tory neuronal activity, such as reduced locomotor and
general activity, abnormal gait and constant tremor, but have
a normal life span and reproduce normally (Chiu et al., 2005).
This suggests that other GABA transporters can replace GAT-1
activity or that other components of GABA signalling adapt
to reduced neurotransmitter clearance (Bragina et al., 2008).
Similarly, there is overlap between the function of noradrena-
line and dopamine transporters. For example, there is evi-
dence that NET is responsible for clearance of extracellular
dopamine in the prefrontal cortex (see Carboni and Silvagni,
2004). By contrast, there appears to be little overlap between
the function of glycine transporters GlyT1 and GlyT2, due to
differential localization (Eulenburg et al., 2005). The amino
acid transporters NTT4 and B°AT2 seem to have a very similar
distribution in the brain, providing redundancy for the
uptake of essential amino acids into neurons (Masson et al.,
1996).
Pathology and clinical significance
Members of the SLC6 family are believed to play a role in a
variety of disease states. In a number of cases, mutations in a
transporter are associated with an inherited Mendelian disor-
der. In some cases, mutations contribute to more complex
multifactorial diseases and in others disorders of unknown
aetiology can be treated by inhibitors of SLC6 transporters.
Table 5 provides an overview of disease states associated with
the SLC6 family.
Table 4
SLC6 transporters as drug targets
Transporter Drug/Drug class Indication Comment
GAT1 Tiagabine Epilepsy, neuropathic pain
NET NRI ADHD, depression
NDRI ADHD, depression, obesity
SNRI Depression, neuropathic pain
Tricyclic antidepressants Depression, neuropathic pain
DAT NDRI ADHD, depression, obesity
SERT SSRI Depression, anxiety, OCD
SNRI Depression, neuropathic pain
TauT Taurine No specific condition Dietary Supplement
CT1 Creatine Athletic sport Dietary Supplement
Creatine deficiency syndromes
NRI, noradrenaline reuptake inhibitor; NDRI noradrenaline/dopamine reuptake inhibitor; SNRI, serotonin/noradrenaline reuptake inhibitor;
SSRI, selective serotonin reuptake inhibitor.
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Creatine deficiency syndrome is a rare disorder caused by
mutations in the creatine transporter CT1 (Salomons et al.,
2001). It causes creatine deficiency in the brain resulting in
mental retardation. Creatine is an important storage com-
pound for high-energy phosphate bonds, which replenish
ATP during times of high energy consumption (Wallimann
et al., 2011). Mutations in the glycine transporter GlyT1 cause
hyperekplexia, an exaggerated startle syndrome, resulting
from increased inhibition in motor circuits (Harvey et al.,
2008). Mutations in B0AT1 are associated with Hartnup dis-
order, an amino acid malabsorption syndrome, which can
cause skin rash and ataxia in young individuals (Seow et al.,
2004). Mutations in IMINO are associated with iminoglycinu-
ria, a benign disorder affecting reabsorption of glycine and
proline in the kidney (Broer et al., 2008).
The noradrenergic system plays an important role in
depression, attention, vigilance, learning, memory and has
been proposed to contribute to ADHD (Hahn and Blakely,
2007). It is also involved in blood pressure regulation through
its role in the peripheral nervous system. DNA and protein
variants of NET are associated with disorders of the noradren-
ergic system. An inactivating mutation in NET is associated
with orthostatic intolerance (Shannon et al., 2000; Hahn
et al., 2003), and another variant was identified by analysing
candidate genes for blood-pressure homeostasis (Halushka
et al., 1999). Interestingly, this variant has also been associ-
ated with major depression (Haenisch et al., 2009). However,
NET is only one component in the noradrenergic systems,
and other variations in receptors, synthesizing and degrading
enzymes, and also in environmental factors, all can contrib-
ute to the phenotype of these disorders.
The dopaminergic system is an important mediator of
motor function, cognition, mood, reward and addiction. The
dopaminergic system is associated with a variety of disorders,
such as ADHD, bipolar disorder, autism, schizophrenia, drug
abuse, Parkinson’s disease and Tourette’s syndrome (Hahn
and Blakely, 2007). Of interest, DAT knock-out mice display a
behavioural phenotype that in part resembles symptoms seen
in ADHD patients (Gainetdinov and Caron, 2000) and in
agreement a single point mutation (Ala559Val) has been iden-
tified in patients with ADHD (Mazei-Robison et al., 2005).
Furthermore, two inactivating mutations in DAT have been
linked to the rare autosomal-recessive disease, infantile
parkinsonism-dystonia (Kurian et al., 2009).
5-HT plays a role in mood, aggression, response to
alcohol, appetite, sleep, cognition and sexual and motor
activity. It is likely to contribute to a range of mental illnesses
such as depression, suicide, anxiety, autism, OCD, eating
disorders, schizophrenia and alcohol abuse (Hahn and
Blakely, 2007). Indeed, many polymorphisms have been
identified in SERT, including, for example, both rare protein
variants in patients with various neuropsychiatric disorders
and an intensively studied promoter variant (Hahn and
Blakely, 2007). The general significance of the promoter
variant (5HTTLPR) has been debated (Munafo et al., 2009;
Risch et al., 2009). Nonetheless, several studies have linked
the short ‘s’ allele to anxiety-related personality traits,
increased risk for neuropsychiatric disorders, impulsive
behaviour and impaired response to antidepressant treatment
(Hahn and Blakely, 2007; Serretti et al., 2007; Homberg and
Lesch, 2011). It has been proposed that these phenotypic
traits in people carrying the ‘s’ allele are caused by hypervigi-
Table 5
Disease states associated with SLC6 family transporters
Transporter Disease state Inheritance Variation Reference
NET ADHD Complex Promoter variants Kim et al. (2006)
Depression Complex Hahn and Blakely (2007)
Orthostatic intolerance Complex A457P Shannon et al. (2000)
Blood pressure Complex Halushka et al. (1999)
SERT Autism/OCD Complex VNTR, SNPs Cook et al. (1997); Sutcliffe et al. (2005)
OCD Complex I425V
Anxiety/Depression Complex VNTR Ozaki et al. (2003)
VNTR Lesch et al. (1996)
L255M
DAT ADHD Complex 3′ VNTR Hahn and Blakely (2007)
Bipolar Complex Several SNPs Grunhage et al. (2000)
Tourette syndrome Complex 3′ VNTR Tarnok et al. (2007)
GlyT2 Hyperekplexia Mendelian Various mutants Rees et al. (2006)
Creatine X-linked mental retardation Mendelian Various mutants Salomons et al. (2001)
B0AT1 Hartnup disorder Mendelian Various mutations Kleta et al. (2004); Seow et al. (2004)
B0AT2 Major depression Complex Downstream of the gene Kohli et al. (2011)
IMINO Iminoglycinuria Mendelian T199M Broer et al. (2008)
VNTR, Variable number of tandem repeats; a short nucleotide sequence organized into clusters of tandem repeats.
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lance and thereby supersensitivity to environmental cues.
This supersensitivity might cause enhanced emotional
responses that could contribute to development of pathologi-
cal conditions (Homberg and Lesch, 2011).
Recently, a genome-wide association study has suggested
B°AT2 as a candidate gene involved in major depression
(Kohli et al., 2011). It should be noted that SNPs associated
with major depression are significantly downstream of the
gene, and a more causal relation needs to be established.
The role of taurine transport in human physiology is still
ill understood. Taurine transporter deficient mice show a
variety of pathological features, such as subtle derangements
of renal osmoregulation, changes in neuroreceptor expres-
sion and loss of long-term potentiation in the striatum (War-
skulat et al., 2007). They develop clinically relevant age-
dependent disorders, for example, visual, auditory and
olfactory dysfunctions, non-specific hepatitis and liver fibro-
sis (Warskulat et al., 2004). It is thought that taurine is an
important osmolyte for cells, but the relative vulnerability of
cells to lack of taurine has yet to be assessed. No human
disorder has been identified involving the taurine transporter.
Distribution
Members of the SLC6 family are found in a wide variety of
tissues (Table 6). The neurotransmitter transporters are
mainly found in the CNS. However, many neurotransmitters
are also used as signalling molecules by peripheral neurons
and chromaffin cells. The amino acid transporters are not
only found in epithelial cells, mostly in the intestine and
kidney, but also in brain, lung and testis. Taurine and creatine
transporters are expressed widely. Apart from NTT4 (Parra
et al., 2008) and PROT (Velaz-Faircloth et al., 1995), two
amino acid transporters found in vesicular compartments in
the brain, all other SLC6 family transporters are located pri-
marily in the plasma membrane. Neurotransmitter transport-
ers in the brain are either localized in the presynaptic
membrane to recapture released neurotransmitters or are
localized in astrocytes, which remove neurotransmitters and
modulate neurotransmission by a variety of mechanisms.
Monoamine transporters, for example, are found in the
plasma membrane of the presynaptic neurons using the cor-
responding neurotransmitter. By contrast, the GlyT1 is
expressed in astrocytes and its distribution correlates with
that of the NMDA receptor (Smith et al., 1992a). As a result it
is thought to modulate glutamatergic neurotransmission.
During development, it is in addition important for removal
of the inhibitory neurotransmitter glycine (Eulenburg et al.,
2010). The glycine transporter GlyT2 is found mainly in
neurons of the spinal cord, where it recaptures glycine
released from inhibitory neurons (Liu et al., 1993a). The
GABA transporter GAT-1 is found in inhibitory neurons
throughout the cortex. GAT-2 is found in the leptomeninges
Table 6
Tissue and cellular distribution of SLC6 family transporters
Transporter Endogenous substrate Main organ Other tissues Subcellular
SLC6A1/GAT1 GABA brain Bladder, liver, parathyroid PM, presynaptic
SLC6A2/NET noradrenaline brain Intestine, kidney, placenta, testis PM, presynaptic
adrenal gland
SLC6A3/DAT dopamine brain thymus PM, presynaptic
SLC6A4/SERT 5-HT brain Bone, intestine, thymus PM
SLC6A5/GlyT2 glycine spinal cord Brain, eye PM, presynaptic
SLC6A6/TauT taurine ubiquitous PM
SLC6A7/PROT proline brain Vesicular
SLC6A8/CT1 creatine ubiquitous PM
SLC6A9/GlyT1 glycine widely PM
SLC6A10 pseudogene n.a.
SLC6A11/GAT3 GABA brain Eye, spinal cord PM
SLC6A12/BGT1 betaine, GABA kidney Brain, liver PM
SLC6A13/GAT2 GABA kidney, liver Brain, eye PM
SLC6A14/ATB0,+ Neutral and cationic amino acids lung Pituitary, colon, mammary gland PM
SLC6A15/B0AT2 BCAA, Met, Pro brain Eye, muscle, placenta PM
SLC6A16/NTT5 Unknown testis Blood, bone unknown
SLC6A17/NTT4 BCAA, Met, Pro, Ala, Gln brain Eye, pituitary, pancreas Vesicular
SLC6A18/B0AT3 Gly, Ala kidney PM
SLC6A19/B0AT1 Neutral amino acids kidney, intestine skin PM
SLC6A20/SIT1 Pro, OH-Pro, betaine intestine Brain, eye PM
BCAA, branched chain amino acid; PM, plasma membrane.
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surrounding the brain, while GAT-3 has been reported in
astrocytes and neurons. The GABA-betaine transporter BGT-1
is also found in neurons but not in the presynaptic mem-
brane. Amino acid transporters of the SLC6 family, such as
B0AT1, B0AT3 and IMINO, are found in the apical membrane
of epithelial cells in the kidney and intestine, where they
remove amino acids from the lumen (Romeo et al., 2006;
Vanslambrouck et al., 2010). In addition, there are two
neutral amino acid transporters (NTT4 and B0AT2), which are
found in neurons throughout the brain (Masson et al., 1996).
Regulation
Many members of the SLC6 family are highly regulated,
involving multiple protein–protein interactions. These can be
direct interactions between the transporter and another
protein or involve a post-translational modification such as
phosphorylation (see, e.g., Ramamoorthy et al., 2011) or ubiq-
uitination (Miranda and Sorkin, 2007) of a transporter, mostly
at the N- or C-terminus, followed by recognition of the modi-
fied sequence by other proteins (Figure 2). In most cases, this
results in changes of transporter localization, with changes of
catalytic activity being less common (Apparsundaram et al.,
2001; Zhu et al., 2005). Changes of transporter localization
can occur in different ways: first, attachment of a protein can
result in movement of the transporter from intracellular
membranes to the cell surface; second, attachment of a
protein can result in withdrawal of the transporter from the
cell surface; third, attachment of a protein can result in sta-
bilization and retention of the protein at the cell surface.
Monoamine transporters in addition are regulated by sub-
strate binding, which can affect phosphorylation and traffick-
ing. A variety of SLC6 transporters undergo continuous
constitutive internalization into endosomal compartments
conceivably followed by recycling back to the plasma mem-
brane (Torres et al., 2003; Melikian, 2004; Eriksen et al., 2010;
Ramamoorthy et al., 2011). This process can be affected by
activation of kinases, binding of substrate and interaction
with other proteins (Figure 2). The number of studies demon-
strating protein–protein interactions and protein phosphor-
ylation are too numerous to be listed exhaustively. Instead,
the reader is referred to recent reviews in this area (Melikian,
2004; Sitte et al., 2004; Torres, 2006; Eriksen et al., 2010;
Ramamoorthy et al., 2011). A few examples serve to illustrate
these different mechanisms; (i) Movement to the cell surface
by protein–protein interactions. Two different mechanisms
are observed, either transporters dimerize before exit from the
endoplasmic reticulum can occur (Schmid et al., 2001; Farhan
et al., 2006; Horschitz et al., 2008), or they need to associate
with an accessory protein, such as collectrin or ACE2 (B°AT1
and B°AT3) (Danilczyk et al., 2006; Kowalczuk et al., 2008;
Vanslambrouck et al., 2010). These mechanisms are not exclu-
sive, because SERT, for instance, requires both dimerization
and binding to the cargo protein SEC24C to reach the surface
(Sucic et al., 2011). (ii) Withdrawal from the cell surface. Many
neurotransmitter transporters are withdrawn from the surface
into endosomal compartments after treatment of cells with
agents that activate PKC (Ramamoorthy et al., 2011). In most
cases, this is accompanied by increases in transporter phos-
phorylation on the amino-terminus or the carboxyl-terminus.
However, mutagenesis of canonical phosphorylation sites in
DAT did not affect down-regulation (Foster et al., 2002). It
rather appears that PKC-mediated down-regulation requires
sequestration of the transporters in specific membrane
domains, such as lipid rafts (Jayanthi et al., 2004; Cremona
et al., 2011). For DAT, PKC-mediated down-regulation might
also depend on N-terminal ubiquitination (Miranda and
Sorkin, 2007) and/or binding of the Ras-like GTPase, Rin, to
an endocytic motif in the C-terminus (Navaroli et al., 2011).
Whether similar mechanisms account for other SLC6 trans-
porters and whether other kinds of adaptor proteins are
required remains unclear. (iii) Stabilization of transporters in
the membrane/synapse: Many SLC6 transporters contain a
C-terminal PDZ (PSD-95/Discs-large/ZO-1 homology) binding
sequence, enabling binding to ‘scaffolding’ proteins contain-
ing PDZ domains. As an example, the PDZ domain protein
syntenin-1 binds the C-terminus of GlyT2, and mutation of
the PDZ binding motif reduces synaptic localization of this
transporter, suggesting that syntenin-1/ or another PDZ
domain protein is involved in stabilizing the transporter at
synaptic sites (Armsen et al., 2007). Of interest, DAT and NET
both bind to PICK1 (protein interacting with C-kinase-1), and
this interaction was suggested to play a role in synaptic tar-
geting of DAT (Torres et al., 2001). However, later results have
questioned this function, and the functional significance of
Figure 2
Regulation of SLC6 transporters. Major mechanisms regulating trans-
porter activity and localization are illustrated. In (1), in order to be
trafficked to the cell surface, transporters (shown in green) often
need to dimerize or associate with a trafficking subunit (orange). At
(2), fusion of vesicles with the plasma membranes occurs through
interaction of t-SNARE and v-SNARE proteins, shown as helices. Once
in the cell membrane (3), a variety of neurotransmitter transporters
interact with the t-SNARE protein syntaxin1A (helix) or with the
trafficking subunit (orange). To stabilise localisation in the cell mem-
brane (4), transporters can interact with scaffolding proteins, such as
PDZ domain-binding proteins (shown as brown globular structures).
These can anchor transporters to the cytoskeleton, shown as orange
filaments. Internalization of transporters frequently starts with phos-
phorylation of the N-terminus or C-terminus of transporters and this
phosphorylated form is recognized by adapter proteins (5), causing
internalization and subsequent removal of the transporter to endo-
somal compartments (6). Internalization often occurs in specialized
lipid domains, such as lipid rafts.
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the DAT/PICK1 interaction remains unsettled (Bjerggaard
et al., 2004).
A notable but still poorly understood protein–protein
interaction is the interaction of syntaxin1A with members of
the SLC6 family. Syntaxin1A has been shown to interact with
GAT1 (Beckman et al., 1998), DAT (Lee et al., 2004; Binda
et al., 2008), NET (Sung et al., 2003), SERT (Quick, 2003),
GlyT1 and GlyT2 (Quick, 2006). Syntaxin 1A is a t-SNARE
protein, which resides in the plasma membrane and catalyses
the fusion of synaptic and other vesicles with the plasma
membrane. Syntaxin1A appears to interact directly with the
N-terminus of several neurotransmitter transporters exerting
a variety of effects. First, it seems to be important for move-
ment of transporters from vesicular compartments to the
plasma membrane (Geerlings et al., 2001) as shown by
decreased trafficking of NET to the surface after partial pro-
teolysis of syntaxin1A with botulinum toxin C1 (Sung et al.,
2003). Second, as suggested for SERT, interaction of the trans-
porter with syntaxin1A can reduce transport activity by inter-
fering with an interaction between the N-terminus and
intracellular loop 4 (Quick, 2003). Syntaxin1A also abolishes
the transport-associated ion conductance in SERT (Quick,
2003). Finally, syntaxin1A binding can promote reverse trans-
port of substrate such as, for example, amphetamine-induced
efflux of dopamine in DAT (Binda et al., 2008). Taken
together, while there is no question that syntaxin 1A affects
neurotransmitter transporter activity in a variety of ways, the
physiological rationalization of these processes is far from
complete. Interestingly, collectrin, which traffics B0AT1 and
B0AT3 to the membrane, is thought to interact with Snapin,
another t-SNARE protein (Fukui et al., 2005).
Biochemistry
The structure of SLC6 neurotransmitter transporters has been
probed intensively, using site-directed mutagenesis, alanine
scanning, cysteine accessibility and other approaches
(Kanner, 2006; Kristensen et al., 2011). The advent of the
high-resolution structure of the bacterial homologue, the
leucine transporter LeuT, however, has provided a quantum
leap to our understanding of the SLC6 structure (Yamashita
et al., 2005). Overall SLC6 transporters have 12 transmem-
brane helices, 10 of which constitute the core of the trans-
porter. The additional two helices might be involved in
transporter dimerization (Just et al., 2004). The first 10 helices
are arranged in a pseudo-twofold symmetric pattern, named
the 5 + 5 inverted repeat fold (Figure 3). The first five helices
can be converted into the second five helices by a simple
symmetry operation. Interestingly, the ‘5 + 5 inverted repeat’
of LeuT has been identified also in structures of other
prokaryotic transporters, which belong to families that lack
significant sequence identity to LeuT or other SLC6 transport-
ers and, accordingly, were not expected to be structurally
related (see Abramson and Wright, 2009; Forrest and
Rudnick, 2009). Hence, the 5 + 5 inverted repeat fold
observed in LeuT appears to characterize several families of
secondary active transporters that are likely to operate via a
conserved molecular mechanism (see Abramson and Wright,
2009; Forrest and Rudnick, 2009; Krishnamurthy et al., 2009;
Forrest et al., 2011). Of particular interest are helices 1 and 6,
A
B
Figure 3
Structure of SLC6 family transporters. The structure of the prokaryo-
tic leucine transporter LeuT is used as a template to generate homol-
ogy structures of SLC6 transporters. In (A) the structure of LeuT is
shown in the open-outside conformation (Protein database 3TT1)
and in (B) as the open-inside conformation (Protein database 3TT3).
Its structure is characterized by an inverted repeat of a group of five
helices. Helices 1–5 are shown in blue and helices 6–10 in orange.
Extracellular loop 4 is shown in magenta. Helices 11 and 12 are
omitted for clarity. Note the significant movement of helix 1b to
allow substrate access on the inside. Extracellular loop 4 blocks access
from the outside in the open-inside conformation.
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which are unwound in the center allowing backbone contacts
with Na+ ions and substrate (Table 7). Helix 1 and 6 are
therefore subdivided into helix 1a/1b and helix 2a/2b. Using
site-directed mutagenesis, Krishnamurthy and Gouaux
(2012) were able to crystallise LeuT in a substrate-free
outward-open and inward-open conformation, providing
insight into the transport mechanism. It appears that helices
1,2,5,6 and 7 make significant moves during the transport
cycle; while the remaining helices form a scaffold. In particu-
lar, helix 1a bends around the center opening up the cytosolic
access. In the inward-open conformation, access from the
outside is blocked by helices 1b and 6a and extracellular loop
4 (Figure 3).
All SLC6 family members have a high-affinity substrate
binding site in the centre of the membrane, called the S1
site. In the initial LeuT structure, which was captured in an
occluded outside-facing conformation (Yamashita et al.,
2005), access to the S1 site from the extracellular side is
prevented by a network of interactions extracellular to S1
that is generated by side chains from TM1, TM3, TM6 and
TM10. This includes a highly conserved Arg in TM1 (Arg30 in
LeuT) that interacts via a pair of water molecules with an
Asp in TM10 (Asp404 in LeuT) (Yamashita et al., 2005). Access
to S1 from the intracellular medium is obstructed by a large
layer of protein intracellular to S1 that contains a network of
interactions formed primarily by residues at the cytoplasmic
ends of TM1, TM6 and TM8 (Yamashita et al., 2005). A
highly conserved key residue is Tyr268 (LeuT numbering) that
by forming a cation–p interaction with Arg5 in the
N-terminus just below TM1 stabilizes a salt bridge between
the arginine and Asp369 at the bottom of TM8 (Yamashita
et al., 2005). Together, these external and internal networks
are believed to form dynamic gates that sequentially allow
access to the substrate binding site from the extracellular
and intracellular environments, respectively, during the
transport cycle.
It is assumed that substrate binding together with Na+
leads to conformational changes that close the external gate
and occlude the substrate. In the case of LeuT, two Na+ ions
bind together with the substrate in the active site. Recent
site-directed spin labelling and electron paramagnetic reso-
nance (EPR) analysis on purified LeuT demonstrated the
Na+-dependent formation of a dynamic outward-facing
intermediate that exposes the primary substrate binding site
and the conformational changes that occlude this binding
site upon subsequent binding of leucine (Claxton et al.,
2010). The free energy of the new closed conformation is
such that a larger conformational change can now occur
fairly easily (by thermal movement), leading to the open-
inside structure with access to the cytosol. In the last step, the
gate on the inside opens allowing the substrate to be released.
Notable is the bending of helix 1a, which provides access
from the cytosol in the open-inside structure. This latter
event might be triggered by binding of a second substrate to
the outer vestibule in LeuT; hence, steered molecular dynam-
ics have suggested the existence of a second substrate binding
site (S2) in the vestibule extracellular to the primary binding
site (S1) (Shi et al., 2008). The existence of this S2 site has
been further supported by single molecule FRET studies of
conformational changes in the LeuT (Zhao et al., 2011).
However, the existence and role of this binding site is con-
troversial, and other sets of data have supported the presence
of only one substrate binding site in the LeuT structure (Pis-
citelli et al., 2010). The structural basis of transport-associated
conductances also remains unclear but appears to be in equi-
librium with the inward facing conformation in the case of
the SERT (Schicker et al., 2012). It is tempting to speculate
that movements of extracellular loop 4 could allow formation
of a continuous, water-accessible, pathway through the
transporter.
In the context of the transport mechanism of the SLC6
family, chloride co-transport is another important feature. A
plausible chloride binding site has been identified in
chloride-dependent members of the SLC6 family (Forrest
et al., 2007; Zomot et al., 2007). In Cl--independent members
of the family, such as LeuT and Tyt1 (another prokaryotic
transporter), the site is occupied by a negatively charged
glutamate residue. In Tyt1, substrate transport measured after
reconstitution into liposomes was stimulated by an inversely
oriented pH gradient, and correspondingly, mutation of Ser331
in the Cl- binding site of GAT1 to glutamate conveyed pH
dependency to this transporter. The data suggest that in Cl-
independent members of the family, a proton may bind and
unbind during the transport cycle and thus be counter-
transported by a Na+/substrate–coupled H+ anti-port mecha-
nism, possibly to facilitate the return step of the ‘empty’
transporter. This ensures a charge balance among the SLC6
transporters with similar mechanistic features but different
molecular solutions (Zhao et al., 2010).
The availability of the LeuT structures also provides rel-
evant clues for the pharmacology of the SLC6 transporters.
In LeuT, the substrate binding pocket is lined by residues
from helices 1, 3, 6 and 8 (Table 7). The pocket has two
regions: first, unwound segments of helices 1 and 6 form
backbone contacts with the a-amino and a-carboxyl group
of the substrate; second a hydrophobic pocket is formed by
aliphatic side chains from TM1, TM3 and TM6 (Tyr108, Phe253,
Ser356, Phe259, Ser355 and Ile359) (Yamashita et al., 2005). Func-
tional studies and homology modelling suggests that the
equivalent residues in the mammalian SLC6 family form the
binding sites for its substrates (Beuming et al., 2006; Rudnick,
2006; Henry et al., 2007). An overview of the equivalent resi-
dues is shown in Table 7. Interestingly, LeuT has been crys-
tallized also together with TCAs as well as with two SSRIs,
fluoxetine and sertraline, for which LeuT displays low affin-
ity. The structures showed a binding site for TCAs and SSRIs
in the LeuT, located in the extracellular vestibule (S2) (Singh
et al., 2007; Zhou et al., 2007; 2009). On the basis of these
observations and mutagenesis of the corresponding site in
SERT, it was proposed that the high-affinity binding site of
TCAs and SSRIs is also located at the putative S2 site in SERT
(Zhou et al., 2007; 2009). However, other studies have sug-
gested that both SSRIs (S-CIT, fluoxetine and sertraline) and
TCAs (CMI, imipramine, and amitriptyline) are classical
competitive inhibitors and that their primary, high-affinity,
binding site is located in the substrate binding pocket (S1)
(Barker et al., 1998; Henry et al., 2006; Andersen et al., 2009;
Sarker et al., 2010; Sinning et al., 2010). Similarly, there is
strong evidence that DAT inhibitors such as cocaine and
benztropines have their high-affinity binding site in the
central substrate binding cavity (Beuming et al., 2008; Bis-
gaard et al., 2011).
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Conclusion
Transporters of the SLC6 family are involved in a wide variety
of pathological conditions. The structure of the bacterial
transporter LeuT allows the generation of homology models,
which will help in the design of new inhibitors, targeting
specific SLC6 transporters. The pharmacology of the
monoamine transporters is highly developed, but the bio-
medical relevance of other transporters in this family is less
well explored.
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